A phase I clinical trial (NCT03528642) for IDH mut glioma testing with CB-839 (Telaglenastat) a GLS inhibitor showed that Telaglenastat decreases the intracellular Glu and GSH levels in glioma cells and increases the radiotherapy efficacy in vivo [235]. This evidence concerns the gene IDH1 and glioma.